Nuvation Bio's SWOT analysis: oncology firm's stock faces pivotal year

Published on January 7, 2025

opportunities and making it easier to raise capital for advancing other pipeline candidates. The revenue from taletrectinib could fund

Continue reading on website
Other news

IDEAYA Biosciences' SWOT analysis: oncology biotech stock's potential and risks

January 7, 2025
Analysts TargetsRBC Capital Markets: $61.00 (November 11th, 2024) RBC Capital Markets: $61.00 (September 24th, 2024) RBC Capital Markets:

HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements

January 7, 2025
Other Information About HOOKIPA Investors and others should note that we announce material financial information to our investors using our